Achieving stable remission with maintenance electroconvulsive therapy in a patient with treatment-resistant schizophrenia

A case report

Sebastian Moeller, MD,∗, Neelle Kalkwarf, MD, Caroline Lücke, MD, Diana Ortiz, MD, Sonja Jahn, MSc, Christiane Först, MD, Niclas Braun, MSc, Alexandra Philipson, MD, Helge H.O. Müller, MD

Abstract

Rationale: Up to one third of all schizophrenic patients are classified as having treatment-resistant schizophrenia (TRS). This subgroup faces remarkable medical and psychosocial damages, and pharmacotherapy is often limited due to nonresponse and/or side effects. Maintenance electroconvulsive therapy (M-ECT) might be effective in TRS.

Patient concerns: We present a case of a 26-year-old male patient with a TRS.

Diagnoses: He received a treatment series of ECT sessions and a course of 24 M-ECTs.

Interventions: The entire treatment was tolerated without significant side effects.

Outcomes: Moreover, the Psychotic Symptom Rating Scale (PSYRATS) scores for both positive and negative symptoms decreased and remained stable over the course of M-ECT.

Lessons: Because of the remarkable improvement in the negative and positive symptom clusters, we propose systematic examinations in the field of M-ECT in TRS patients. These studies should integrate long-term outcome and tolerance measurements, gaining insight into the optimal duration of treatment for this indication.

Abbreviations: ECT = electroconvulsive therapy, M-ECT = maintenance electroconvulsive therapy, PSYRATS = Psychotic Symptom Rating Scales, RCT = randomized controlled trial, TRS = treatment-resistant schizophrenia.

Keywords: electroconvulsive therapy, maintenance electroconvulsive therapy, neurostimulation, remission, treatment-resistant schizophrenia.

1. Background

Up to one third of patients with schizophrenia are classified as having treatment-resistant schizophrenia (TRS),[1–6] the diagnostic criteria for which[7–11] include lack of response to 2 different antipsychotic trials or clozapine, intolerance of antipsychotic drug side effects, and relapse or symptomatic deterioration even when taking sufficient doses of the appropriate medication.[12–13]

Other widely accepted criteria of TRS include an illness duration of >5 years; psychotic-associated symptoms that show no significant improvement after 2 years of regular, full-dose/full-course treatment with 2 kinds of antipsychotics; and, especially, no response to clozapine.[16–23]

Although clozapine is the criterion standard for the treatment of patients with TRS, clinical symptoms persist in approximately 40% to 70% of clozapine users.[22,24–26] For TRS and/or clozapine non- or partial response in TRS, in addition to a variety of pharmacological and nonpharmacological approaches, electroconvulsive therapy (ECT) has been attempted as an adjunct therapy for schizophrenia, especially when a rapid improvement and symptom reduction is desired.[20,27–31] ECT, first developed in the 1930s by Bini and Cerletti, is a key neurostimulation tool within the therapeutic armamentarium in clinical psychiatry for severe and life-threatening psychiatric diseases, particularly depressive diseases but also in cases of TRS.[12] In an extensive Cochrane review on randomized controlled trials (RCTs) comparing real and sham ECT for schizophrenia, a larger
improvement was found for those patients that received real ECT. Moreover, several studies have demonstrated the efficacy of ECT for patients with TRS. Among other things, fewer relapses and a greater likelihood of an earlier discharge from the hospital were observed after ECT. Moreover, a longer treatment series with 20 electroconvulsive treatments was more efficient than a shorter treatment series with 12 treatments. Hence, these findings indicate that ECT might be a valuable adjunct therapy to antipsychotic medication in TRS.

Although ECT might be considered a promising adjunct therapy for TRS, there are insufficient empirical data on the duration of the beneficial antipsychotic effects of ECT. In fact, no controlled RCTs have investigated ECT maintenance treatment (M-ECT) in TRS. M-ECT characterizes the maintenance treatment after successful treatment of an index phase, mostly in major depression and especially in depression with psychotic symptoms. However, M-ECT might also be effective in TRS.

Here, we present the case of a 26-year-old chronic psychotic patient who improved remarkably and whose psychotic symptoms remained stable after continuously receiving M-ECT.

### 2. Case presentation

The 26-year-old male patient had been followed-up for schizophrenia for approximately 3 years after suffering from fluctuating paranoid-hallucinatory symptoms since he was 20 years old. Therefore, the diagnosis of paranoid schizophrenia was made by multiple psychiatrists. No family history of neurological or psychological illness was identified. Despite taking neuroleptics, in the course of the disease, the patient experienced 4 episodes (for several weeks) with paranoid-hallucinatory exacerbation. In these episodes, the patient suffered from formal thought disorders, fear, and delusions of persecution; auditory hallucinations with commenting, discussing, and commanding voices; visual hallucinations involving seeing persons in his room; and tactile hallucinations with the feeling of being touched from behind. In parallel to these exacerbations, the patient developed memory deficits, fatigue, depressive mood, and sleep disturbances, and thus completing the psychopathological features of comprehensive schizophrenia. Neurological and medical examinations showed no further clinical disorders. The patient had been treated with amisulpride, benperidol, chlorprothixene, levomepromazine, olanzapine, and clozapine at standard doses and for an adequate period of time. Because he did not properly respond to any of these medications, we diagnosed him as having TRS and initiated an individual treatment regime with M-ECT. In total, 24 ECT treatments were administered over a 1-year period,
and the treatment success was evaluated by the Psychotic Symptom Rating Scales (PSYRATS), (Table 1). Before beginning ECT treatment, the patient showed clear deficits in almost every PSYRATS subscale; however, after 24 ECT treatment sessions, the symptom severity was much weaker and limited to only some of the PSYRATS subscales (see tables). His neuroleptic medication, olanzapine (10 mg given morning and night), remained stable during the treatment course. Moreover, there was no need for add-on psychiatric in-hospital treatment during the whole M-ECT treatment course (Table 2).

3. Discussion

Treatment of TRS is generally challenging. Our patient with TRS received different neuroleptic drugs at standard doses for an adequate period of time, none of which led to a satisfactory outcome as the psychotic symptoms persisted. The patient’s improvement exactly corresponded to the initiation of M-ECT. Moreover, his psychotic symptoms remained stable throughout the course of M-ECT. Despite the symptom reduction, the patient reported a good tolerance and compliance for the M-ECT treatment course. Furthermore, the total and subscale scores of the PSYRATS changed for the better. Our patient’s positive symptoms, that is, delusion and hallucinations, as well as his negative symptoms, that is, blunted affect and emotional withdrawal, improved. Of upmost importance, even a stay at a forensic psychiatry clinic and aggressive tendencies could be prevented due to the treatment.

Although the use of ECT in acute or even life-threatening phases of mental illnesses, for example, catatonic conditions, is well known and evidence-based, there is a lack of information regarding M-ECT in chronic and nonresponsive schizophrenic probands.

Our case demonstrates that M-ECT might be a promising option to reduce the likelihood of new psychotic episodes. Moreover, in line with existing literature, the patient did not report any side effects, for example, memory impairment, probably because, unlike acute ECT, the time interval between treatments is longer. However, there is no agreement in the literature on the optimal duration of M-ECT treatment in TRS cases.

Our patient received bilateral M-ECT under general anesthesia. Initially, we performed ECT once a week; later we performed it once every second week followed by ECT once in a month. Because there is not yet a general consensus on the frequency of M-ECT therapy, mostly flexible and individually scheduled weekly/biweekly/monthly courses are used.

We only report 1 single case and thus cannot completely rule out the possibility that our patient’s improvement was independent of the acute and maintenance ECT but was rather a spontaneous remission or unspecific adherence-based effect, for example, frequent welfare during his stays at the hospital. Moreover, the narcosis during ECT might also have influenced the symptoms of our patient. However, the improvement seen in our patient seems to be clearly associated with M-ECT. We thus propose systematic examinations in that field.

To conclude, our case demonstrates the efficacy and safety of M-ECT in a patient with TRS who showed a significant improvement in terms of his positive and negative symptoms. Larger studies should not only examine outcome measurements but also integrate questions of tolerance and the duration of treatment courses.

References

[1] Van Sant SP, Buckley PF. Pharmacotherapy for treatment-refractory schizophrenia. Expert Opin Pharmacother 2011;12:411–34.
[2] Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull 1997;23:663–74.
[3] Gillespie AL, Samanarite R, Mill J, et al. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review. BMC Psychiatry 2017;17:12.
[4] Suzuki T, Remington G, Mulsant BH, et al. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res 2012;197:1–6.
[5] Zheng W, Cao XL, Uyghar G, et al. Electroconvulsive therapy added to non-clozapine antipsychotic medication for treatment-resistant schizophrenia: meta-analysis of randomized controlled trials. PLoS One 2016;11:e0156510.
[6] Painuly N, Gupta N, Avasthi A. Concept and management of treatment-resistant schizophrenia (TRS). Indian J Psychiatry 2004;46:125–34.
[7] Stephens P. A review of clozapine: an antipsychotic for treatment-resistant schizophrenia. Compr Psychiatry 1990;31:315–26.
[8] Warne W, Rossi-Verini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry 2014;14:102.
[9] Wójcik JW, Smith MJ, Keshavan MS, et al. A systematic and meta-analytic review of neural correlates of functional outcome in schizophrenia. Schizophr Bull 2017;43:1329–47.
[10] Yoshimura B, Yada Y, So R, et al. The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. Psychiatry Res 2017;250:65–70.
[11] Zheng W, Xiang YT, Yang XH, et al. Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a meta-analysis of randomized controlled trials. J Clin Psychiatry 2017;78:e498–505.
[12] Kane JM, McGlashan TH. Treatment of schizophrenia. Lancet 1995;346:820–5.
[13] Kane JM. Dosing issues and depot medication in the maintenance treatment of schizophrenia. Int Clin Psychopharmacol 1995;10(suppl 3):65–71.
[14] Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993;162:38–42.
[15] Walsh E, Leese M, Taylor P, et al. Psychosis in high-security and general psychiatric services: report from the UK700 special hospitals’ treatment resistant schizophrenia groups. Br J Psychiatry 2002;180:351–7.
[16] Cheine MV, Wahlbeck K, Rimon M. Pharmacological treatment of schizophrenia resistant to first-line treatment: a critical systematic review and meta-analysis. Int J Psychiatry Clin Pract 1999;3:159–69.
[17] Molins C, Roldan A, Corripio I, et al. Response to antipsychotic drugs in treatment-resistant schizophrenia: conclusions based on systematic review. Schizophr Res 2016;178:64–7.
[18] Kennedy JL, Altar CA, Taylor DL, et al. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol 2014;29:63–76.
[19] Souza JS, Kayo M, Tassell I, et al. Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses. CNS Spectr 2013;18:82–9.
[20] Suzuki T, Remington G, Mulsant BH, et al. Treatment-resistant schizophrenia and response to antipsychotics: a review. Schizophr Res 2011;135:54–62.
[21] Meltzer HY, Lindenmayer JP, Kwentus J, et al. A six month randomized controlled trial of long acting injectable risperidone 50 and 100 mg in treatment resistant schizophrenia. Schizophr Res 2014;154:14–22.
[22] Iasevoli F, Giordano S, Balletta R, et al. Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones. Prog Neuropsychopharmacol Biol Psychiatry 2016;65:34–48.
[23] Rajkumar AP, Chitra C, Bhuvaneswari S, et al. Clinical predictors of response to clozapine in patients with treatment resistant schizophrenia. Psychopharmacol Bull 2011;44:51–65.
[24] Samara M, Leuchter S. Clozapine in treatment-resistant schizophrenia. Br J Psychiatry 2017;210:29–39.
[25] Barber S, Olott U, Corsi M, et al. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database Syst Rev 2017;3:CD006324.
[26] Taylor DM. Clozapine for treatment-resistant schizophrenia: still the gold standard? CNS Drugs 2017;31:177–80.
[27] Lally J, Tully J, Robertson D, et al. Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 2016;171:215–24.
[28] Remington G, Lee J, Agid O, et al. Clozapine’s critical role in treatment resistant schizophrenia: ensuring both safety and use. Expert Opin Drug Saf 2016;15:1193–203.
[29] Nielsen J. Every patient with treatment resistant schizophrenia should know the meaning of the term ‘clozapine’. Acta Psychiatr Scand 2014;130:155–6.
[30] El-Badri S, Mell sop G. Clozapine use and outcomes among patients with treatment resistant schizophrenia. Australas Psychiatry 2011;19:410–4.
[31] Müller HHO, Reike M, Grosse-Holze S, et al. Electroconvulsive therapy hasn’t negative effects on short-term memory function, as assessed using a bedside hand-held device. Ment Illn 2017;9:7093.
[32] Fink M. The mode of action of ECT. Psychopharmacol Bull 1994;30:309–12.
[33] Bhatia SC, Bhatia SK, Gupta S. Concurrent administration of clozapine and ECT: a successful therapeutic strategy for a patient with treatment-resistant schizophrenia. J ECT 1998;14:280–3.
[34] Kurian S, Tharyan P, Jacob KS. Combination of ECT and clozapine in drug-resistant schizophrenia. Indian J Psychiatry 2005;47:245.
[35] Fink M. ECT and clozapine in schizophrenia. J ECT 1998;14:223–6.
[36] Castelnau C, Paillere-Martinet M L, Nartowski M, et al. ECT followed by clozapine treatment in acute situations of schizophrenia. Eur Psychiatry 1998;13:219–20.
[37] Sinclair D, Adams CE. Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials. BMC Psychiatry 2014;14:253.
[38] Leiderman EA. Treatment resistant schizophrenia: therapeutic approaches [in Spanish]. Vertex 2005;16:446–53.
[39] Cervera Enguix S, Seva Fernandez A. Pharmacological treatment resistant schizophrenia [in Spanish]. Actas Esp Psiquiatr 2006;34:48–54.
[40] Suzuki K, Awata S, Takano T, et al. Continuation electroconvulsive therapy for relapse prevention in middle-aged and elderly patients with intractable catatonic schizophrenia. Psychiatry Clin Neurosci 2005;59:481–9.
[41] Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev 2005;CD000076.
[42] Prudic J. Strategies to minimize cognitive side effects with ECT: aspects of ECT technique. J ECT 2008;24:46–51.
[43] Iancu I, Pick N, Seener-Lorsh O, et al. Patients with schizophrenia or schizoaffective disorder who receive multiple electroconvulsive therapy sessions: characteristics, indications, and results. Neuropsychiatr Dis Treat 2015;11:853–62.
[44] Telles-Correia D, Moreira AL, Gama Marques J, et al. The proximity between hallucination and delusion dimensions: an observational, analytic, cross-sectional, multicentre study. Front Psychol 2016;7:1642.
[45] Glick HA, Li P, Harvey PD. The relationship between Positive and Negative Syndrome Scale (PANSS) schizophrenia severity scores and risk for hospitalization: an analysis of the CATIE Schizophrenia Trial. Schizophr Res 2015;166:110–4.
[46] Worku B, Fekadu A. Symptom profile and short term outcome of catatonia: an exploratory clinical study. BMC Psychiatry 2015;15:164.